
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has recently improved its financial position through equity financings and option exercises, leading to increased financing income of $284K for the quarter and $611K year-to-date, reflecting enhanced interest earnings from marketable securities. The company is on track for a full launch of its LIBERTY Endovascular Robotic System in the U.S. by Q2 2026, with significant enhancements to its commercial and production capabilities, including an expanded team and a partnership with a third-party logistics provider. Expectations of accelerating growth from the upcoming product launches in various regions further solidify Microbot’s competitive position, which could justify a premium valuation for the stock.
Bears say
Microbot Medical faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include delays in the commercialization of its LIBERTY system, difficulties in expanding applications to neuro and cardio cases, and setbacks in securing international regulatory approvals, all of which could hinder revenue growth. Additionally, the company is grappling with a lack of near-term profitability, reimbursement headwinds, and potential market penetration issues, which could further impact its financial performance.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares